“CXCR2 inhibitor+enza in pts w/ARSI-resistant #mCRPC…was well tolerated w/…responses in a subset of mCRPC pts. This study provides…evidence that… #myeloid inflammation can fuel mCRPC progression & resistance to AR blockade.” #ProstateCancer nature.com/articles/s4158…

Constant TKI is NOT necessary in IO/TKI regimens. We need to prioritize strategies to de-escalate therapy for better QOL and possibly delaying resistance. Congrats to Roberto Iacovelli and the team for this important work.

New for the October issue— ANXA1 Promotes Tumor #ImmuneEvasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers, by Ding Xiao, Ting Zeng, Wei Zhuang, Zhi-Qiang Xiao et al. bit.ly/3FupTSX #CancerImmunology

Nice to see some VA HSR cross-pollination with Utibe R. Essien, MD MPH bringing his #pharmacoequity concept from a.fib to cancer at #ASCOQLTY23!

Honored to work with such an incredible team! And such a great project!

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma | NEJM nejm.org/doi/10.1056/NE…

Very excited by our results nature showing that IL4R signaling is strongly enriched in myeloid cells that infiltrate mice and lung cancer lesions nature.com/articles/s4158…

Don’t miss “Cancer in 2023” in Cancer Discovery, an excerpt from the AACR #CancerProgressReport 👇🏻

Read the new priority brief— Intracellular K+ Limits #Tcell Exhaustion and Preserves Antitumor Function, by Camille Collier et al. bit.ly/3HJROz3 @OHSUsurgery

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer hmpgloballearningnetwork.com/site/onc/confe…

#BmoreStrong

Now out in Cell Reports Medicine our review on emerging treatments for HER2+ #breastcancer We discuss how survival improvements in this disease set a high bar for new drug development and the need to explore new ways to overcome resistance mechanisms OncoAlert cell.com/cell-reports-m…

Patience and Perseverance from the entire GU team at Tata Memorial Hospital. The Multicentre phase 3 RCT of Adj RT post RCIC+ Chemo accrued the last patient (n=153) Took 8 years but we got there in the end. Phew! Interested in the early results? Coming soon at a conference near you!

🐺 Exciting PhD opportunity in #Wildlife! As a guide, I’m looking for motivated students interested preferably in #quantitativeecology, application of #ecology, or #bioacoustics. Let’s make a difference in wildlife conservation #PhDAdmissions #WildlifeConservation #wildlifeindia

Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche dlvr.it/TFS68C

B7H3 (CD276) is an immune checkpoint and is widely expressed on tumor cell. The B7H3/TROP2 ADC shows significant activity especially in small cell lung cancer and head and neck cancer. Toxicity reflects the payload. B7H3 levels by IHC didn’t correlate with outcome Nature Medicine

Fresh out of press! 🧬🔬We are happy to share our latest work published in Diana Hoffman! shorturl.at/F4qnr A thread🧵 Please, Enjoy and share! #CancerResearch, #PrecisionOncology #CancerTherapeutics

Fantastic Cancer Cell paper by Linghua Wang, MD, PhD MD Anderson Cancer Center revealing new biology in cancer-associated fibroblasts. cell.com/cancer-cell/fu…

🚭 From 1970–2022, declining U.S. smoking rates prevented 3.9 million lung cancer deaths: 👨 2.3M men 👩 1.6M women This saved 76 million years of life! Nearly half of all avoided cancer deaths were from lung cancer prevention. CA: A Cancer Journal for Clinicians OncoAlert